GLP-1 Explained
61 articles

The Drugs

Every GLP-1 medication, explained.

Best Foods to Eat on Ozempic and Wegovy (2026) → Compounded Semaglutide vs Ozempic/Wegovy: Safety, Efficacy, and the FDA Status (2026) → GLP-1 and Addiction: Alcohol, Tobacco & Binge Eating Reward Circuitry → GLP-1 Agonists & Addiction: Dopamine, Alcohol, and the Reward System → GLP-1 Agonists & Alzheimer's Disease: Liraglutide ELAD Trial, Semaglutide Norgaard 2024 JAMA, EVOKE Trial, Type 3 Diabetes, Neuroinflammation → GLP-1 & Alzheimer's Disease: Hölscher 2012 Neuroprotection, Semaglutide LIBRA Trial, GLP-1R in Hippocampus, BDNF Upregulation → GLP-1 & Binge Eating Disorder: How Semaglutide Silences Food Noise → GLP-1 and Bone Density: GIP Receptor Biology, Bone Turnover Markers, Semaglutide Fracture Data, and Why Tirzepatide's Dual GIP/GLP-1 Action Matters for Skeletal Health → GLP-1 Cardiovascular Outcomes: SELECT Trial −20% MACE, LEADER, SUSTAIN-6, REWIND, STEP-HFpEF Heart Failure Data, and the Direct Cardiac Mechanisms Behind GLP-1 Cardioprotection → GLP-1 & Cardiovascular Protection: SELECT Trial (N=17,604), LEADER Trial Liraglutide, Atherosclerosis Plaque Regression, −20% MACE → GLP-1 and Cardiovascular Disease: SELECT Trial → GLP-1 & Heart Failure: STEP-HFpEF Trial, Semaglutide & HFpEF Explained → GLP-1 and Kidney Disease: FLOW Trial Semaglutide in CKD, eGFR Slope Improvement, Proteinuria Reduction, Cardiorenal Syndrome Mechanisms, and UACR as Renal Biomarker → GLP-1 Agonists for NAFLD & NASH: Semaglutide, Liver Fat Reduction & Fibrosis Guide → GLP-1 and NAFLD/NASH: SURMOUNT-NASH Tirzepatide 2024 Data, Hepatic Fat Reduction, Liver Fibrosis Improvement, and ALT Normalization → GLP-1 Agonists for PCOS: Insulin Resistance Mechanism, Liraglutide Ovulation Data, Androgen Excess Reduction, and the Emerging Fertility Evidence → GLP-1 Agonists and PCOS: Insulin Resistance, Fertility & Semaglutide Evidence Guide → GLP-1 Agonists for Pediatric & Adolescent Obesity: Semaglutide & Tirzepatide Guide 2024 → GLP-1 & Sleep Apnea: SURMOUNT-OSA Trial, Tirzepatide AHI Reduction 63%, Semaglutide OSA Data, vs. CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Tirzepatide 2024 Trial, −62.8% AHI Reduction, Pharyngeal Fat Mechanism, Hypoxic Burden Improvement, and Whether GLP-1 RAs Can Replace CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Trial, Tirzepatide AHI Reduction, Upper Airway Fat Mechanism, and Whether GLP-1s Can Replace CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Trial → GLP-1 and Type 2 Diabetes: SUSTAIN Trials (Semaglutide −1.5–1.8% HbA1c), SURPASS Program (Tirzepatide −2.1% HbA1c, 40% Reaching Normal Glucose), Beta-Cell Preservation, T2D Remission, and Why GLP-1 Drugs Are Now First-Line in T2D With CVD (2026) → Mounjaro vs Ozempic for Type 2 Diabetes: 2024 Head-to-Head Guide → Rybelsus (Oral Semaglutide): The Pill Form of Ozempic → Oral Semaglutide (Rybelsus) vs Ozempic: Bioavailability, Absorption & PIONEER Trials → Ozempic Plateau: Why Weight Loss Stalls on GLP-1 and What to Do (2026) → Ozempic Plateau: Why Weight Loss Stalls on GLP-1 Drugs and What to Do (2026) → Ozempic Side Effects: Nausea, Vomiting, Gastroparesis → Ozempic and Semaglutide Side Effects: Nausea Management, Muscle Loss, and Long-Term Safety (2026) → Ozempic vs Wegovy: Same Drug, Different Uses — Which Is Right for You? (2026) → Ozempic vs Wegovy: Same Drug, Different Doses → Ozempic vs Wegovy: Same Drug, Different Doses, Different FDA Approvals Explained (2026) → Ozempic vs Wegovy vs Mounjaro vs Zepbound: Complete 2026 Comparison → Ozempic & Wegovy Side Effects: What to Expect, What to Do (2026) → GLP-1 and PCOS: Insulin Resistance as the Core Driver, Semaglutide Weight Loss Restoring Menstrual Cycles, Testosterone Reduction, Tirzepatide SURMOUNT-PCOS Data, Comparison With Metformin, and the Evidence-Based Protocol for GLP-1 in Polycystic Ovary Syndrome (2026) → Retatrutide (LY3437943): The Triple Agonist That Outperformed Every GLP-1 Drug → Retatrutide & Next-Gen GLP-1 Agonists: Triple Agonist Science, Pipeline & 2026–2028 FDA Timeline → Retatrutide and the Next-Gen GLP-1 Drugs: Triple Agonists Explained → Saxenda vs Ozempic: Liraglutide vs Semaglutide Full Comparison → Semaglutide and Bone Health: What the Research Actually Shows About Fracture Risk → The SELECT Trial: How Semaglutide Became the First Obesity Drug to Prove Cardiovascular Benefit → Semaglutide Hair Loss and Skin Changes: What's Actually Happening and What to Do → Semaglutide and Kidney Disease: The FLOW Trial Results Explained → Semaglutide and Male Fertility: What GLP-1 Drugs Do to Testosterone and Sperm → Semaglutide for Fatty Liver Disease: The MASH Trials That Are Reshaping Hepatology → Semaglutide vs Tirzepatide Weight Loss: STEP 1 (−14.9%), SURMOUNT-1 (−20.9%), GLP-1 + GIP Dual Agonism, Gastric Emptying, Central Appetite Suppression → Semaglutide vs Liraglutide: Ozempic/Wegovy vs Victoza/Saxenda → Semaglutide vs Tirzepatide: Head-to-Head Evidence (2026) → Tirzepatide (Mounjaro vs Zepbound): Dual GLP-1/GIP Agonist → Tirzepatide vs Semaglutide: Which Weight Loss Drug Is More Effective? (2026 Clinical Data) → Tirzepatide vs Semaglutide: Head-to-Head Weight Loss, Side Effects, and Cost (2026) → Tirzepatide vs Semaglutide: Mounjaro vs Wegovy Complete Comparison Guide (2025) → Tirzepatide vs Semaglutide: SURMOUNT-1 (Jastreboff 2022, NEJM, N=2,539, Tirzepatide 15mg −20.9% Body Weight) vs STEP 1 (Wilding 2021, N=1,961, Semaglutide 2.4mg −14.9%), Dual GIP+GLP-1 Agonism vs Mono GLP-1, SURPASS-2 Head-to-Head, and When Each Drug Wins (2026) → Tirzepatide vs Semaglutide Head-to-Head: SURMOUNT-5 Trial Results, 20.2% vs 13.7% Weight Loss, Dual GIP/GLP-1 Mechanism, and Which Patients Benefit Most From Each Agent → Tirzepatide vs Semaglutide: Weight Loss Comparison → Tirzepatide vs Semaglutide: The 2024 Head-to-Head Weight Loss Breakdown → Type 2 Diabetes Remission With GLP-1 and GIP/GLP-1 Agonists: SUSTAIN Trials, Tirzepatide Superiority (2026) → Wegovy Insurance Coverage Guide 2026 → Wegovy vs Zepbound: Semaglutide vs Tirzepatide 2024 Head-to-Head Comparison → Zepbound vs Wegovy: Which GLP-1 Drug Wins for Weight Loss in 2026? →
Related Guides
A resource for your family
Scam calls targeting older adults are at record levels — the FBI logged $7.75 billion in reported losses from adults 60+ in 2025. Our free, no-signup guides show families exactly how the calls work — and the four rules that stop them.
Visit Scam-Proof Your Parents →
Weekly Research Digest
Get the free GLP-1 Protocol Log - plus the weekly digest

A 12-week fillable log: injections and site rotation, side effects, daily protein against a muscle-preservation target, and the page you bring to your prescriber.

No spam. Unsubscribe any time.
Losing weight? Don't lose muscle.
Up to 40% of GLP-1 weight loss can be muscle. The GLP-1 Protein Playbook shows you exactly how to protect it — with 25 high-protein meals that go down easy on a killed appetite.
Get the Playbook → $19